## Consolidated Balance Sheet

#### December 31, 2018

| Assets   |               |
|--|---------------|
| Current assets:  |               |
| Cash   | \$ 6,048,668  |
| Accounts receivable, net of estimated allowance for        |               |
| uncollectible accounts of \$9,719,275 at December 31, 2018 | 4,357,566     |
| Prepaid expenses and other assets                          | 706,724       |
| Total current assets                                       | 11,112,958    |
| Property and equipment:                                    |               |
| Leasehold improvements                                     | 1,187,763     |
| Office furniture and equipment                             | 2,609,777     |
| Construction in process                                    | 215,151       |
| Total property and equipment                               | 4,012,691     |
| Less: accumulated depreciation                             | 1,768,073     |
| Property and equipment, net                                | 2,244,618     |
| Other assets:  |               |
| Deposits   | 167,271       |
| Goodwill   | 80,790,923    |
| Total other assets   | 80,958,194    |
| Total assets   | \$ 94,315,770 |

3 1903-3085160

# **Liabilities and equity** Current liabilities:

| Current liabilities:                           |               |
|--|---------------|
| Accounts payable                               | \$ 175,050    |
| Current portion of notes payable               | 695,000       |
| Accrued expenses                               | 5,452,771     |
| Total current liabilities                      | 6,322,821     |
| Long-term liabilities:                         |               |
| Phantom equity accrual, net of current portion | 354,339       |
| Deferred rent                                  | 936,531       |
| Notes payable, net of current portion          | 40,577,384    |
| Other long-term liabilities                    | 351,399       |
| Total long-term liabilities                    | 42,219,653    |
| Total liabilities                              | 48,542,474    |
| Equity:  |               |
| Additional paid-in capital                     | 56,193,454    |
| Members' capital                               | (6,732,352)   |
| Total TVG-Medulla Holdings, LLC equity         | 49,461,102    |
| Noncontrolling interest - clinics              | (3,687,806)   |
| Total equity                                   | 45,773,296    |
| Total liabilities and equity                   | \$ 94,315,770 |

See accompanying notes to consolidated financial statements.

1903-3085160

## Consolidated Statement of Income

#### Year Ended December 31, 2018

| Patient revenues                                    | \$<br>51,024,817 |
|---|------------------|
| Cost of revenues:                                   |                  |
| Direct labor  | 16,950,184       |
| COGS - products and other                           | 1,047,250        |
| Total cost of revenues                              | <br>17,997,434   |
| Gross profit  | 33,027,383       |
| Operating expenses:                                 |                  |
| Salaries and employee benefits                      | 12,617,890       |
| Selling and marketing                               | 1,727,239        |
| Rent, CAM, tax                                      | 3,570,747        |
| Professional services                               | 1,346,159        |
| Travel  | 238,018          |
| Other services                                      | 2,887,658        |
| Depreciation  | 490,374          |
| Goodwill amortization                               | 8,972,154        |
| Interest expense                                    | 3,901,687        |
| Total operating expenses                            | 35,751,926       |
| Loss from operations                                | (2,724,543)      |
| Nonoperating income:                                |                  |
| Other non-operating income                          | 6,566            |
| Net other income                                    | <br>6,566        |
| Consolidated net loss                               | <br>(2,717,977)  |
| Less net loss attributed to noncontrolling interest | <br>(6,004,085)  |
| Net income attributed to TVG-Medulla Holdings, LLC  | \$<br>3,286,108  |

See accompanying notes to consolidated financial statements.

#### Consolidated Statement of Equity

Years Ended December 31, 2018 and 2017

800,000

\$ 28,859,710 \$

\$ 26,848,150

**Additional Paid-In Capital** Class A Class B Clinic Members' Non-Controlling Interest Subscriptions Common Common **Equity** Capital Clinics Receivable Total Balance at December 31, 2017 - as adjusted \$ 26,848,150 915,594 \$ (7,128,198) \$ (54,854) \$ 50,956,681 \$ 28,059,710 \$ 2,316,279 \$ Net income 3,286,108 3,286,108 Net loss - noncontrolling interest (6,004,085)(6,004,085)Tax distribution (2,595,000)(2,595,000)Accrued interest (1,578)(1,578)Principal payments 7,686 7,686 Redemptions and distributions (430,000)(295,262) 48,746 (676,516)

485,594 \$ (6,732,352) \$

See accompanying notes to consolidated financial statements.

Issuance of Class B common

Balance at December 31, 2018

800,000

\$ 45,773,296

(3,687,806) \$

#### Consolidated Statement of Cash Flows

#### Year Ended December 31, 2018

| Operating activities                                     |    |             |
|--|----|-------------|
| Net loss   | \$ | (2,717,977) |
| Adjustments to reconcile net loss to net cash            |    |             |
| provided by operating activities:                        |    |             |
| Depreciation   |    | 490,374     |
| Amortization of goodwill                                 |    | 8,972,154   |
| Amortization of deferred financing costs                 |    | 208,154     |
| Changes in operating assets and liabilities:             |    |             |
| Accounts receivable                                      |    | (127,679)   |
| Prepaid expenses and other assets                        |    | (196,922)   |
| Deposits   |    | (3,801)     |
| Accounts payable   |    | (138,083)   |
| Accrued expenses   |    | 2,330,118   |
| Phantom equity accrual                                   |    | 158,017     |
| Deferred rent  |    | (76,110)    |
| Net cash provided by operating activities                |    | 8,898,245   |
| Investing activities                                     |    |             |
| Cash paid for business acquisition, net of cash acquired |    | (346,950)   |
| Purchase of property and equipment                       |    | (632,832)   |
| Net cash used in investing activities                    |    | (979,782)   |
| Financing activities                                     |    |             |
| Proceeds from issuance of notes payable                  |    | 456,728     |
| Principal payments on debt                               |    | (770,000)   |
| Payments received on subscriptions receivable, net       |    | 54,854      |
| Issuance of Class B Common                               |    | 800,000     |
| Purchase of clinic director equity                       |    | (725,262)   |
| Tax distribution   |    | (2,595,000) |
| Net cash used in financing activities                    |    | (2,778,680) |
| Net increase in cash and cash equivalents                |    | 5,139,783   |
| Cash – beginning of year                                 |    | 908,885     |
| Cash – end of year                                       | \$ | 6,048,668   |
| Cash Cha of year   | Ψ  | 0,040,000   |
| Supplemental disclosures of                              |    |             |
| cash flows information                                   |    |             |
| Cash paid during the period for:                         |    |             |
| Interest   | \$ | 3,984,368   |
| interest   | Ψ  | 3,704,500   |
| Supplemental disclosures of noncash                      |    |             |
| investing and financing activities                       | ¢. | 251 200     |
| Note payable issued for redemption of equity             | \$ | 351,399     |
|  |    |             |

1903-3085160

See accompanying notes to consolidated financial statements.